Skip to main content
Toggle navigation
Login
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
R
Ramakrishnan, Vidya
Genentech, Inc.
(
S-034
)
Pharmacometric analysis of pharmacokinetics, safety, and efficacy data of migoprotafib in combination with divarasib for KRAS G12C-positive non-small cell lung cancer.
Vidya Ramakrishnan
Favorite
Ramesh, Shyam
University of Florida
(
T-043
)
Model-informed Clinical Trial Design for Autosomal Dominant Tubulointerstitial Kidney Disease: Integrating Disease Progression and Trial Simulation
Shyam Ramesh
Favorite
Randolph, Riley
University of North Carolina at Chapel Hill
(
S-103
)
Model-Informed Oral Tacrolimus Dose Optimization for Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post-Transplant Cyclophosphamide
Riley Randolph
Favorite
Rao, Rohit
Pfizer
(
T-090
)
Development and validation of a model-based framework to inform the preclinical to clinical translation of Mpro inhibitor antivirals
Rohit Rao
Favorite
Rattsev, Ilia
Johns Hopkins University
(
M-098
)
Evaluating the impact of pharmacogenomic variants on aromatase inhibitor-induced bone toxicity using a quantitative systems pharmacology model of bone remodeling
Ilia Rattsev
Favorite
Ratushny, Alexander
Bristol Myers Squibb
(
M-014
)
Multiple myeloma QSP model enables evaluation of iberdomide dosing schedules post-ASCT in NDMM patients for the EXCALIBER Maintenance study
Alexander Ratushny
Favorite
Ravva, Patanjali
Pfizer Inc
(
T-087
)
Exposure-Response Analysis of Bleeding Events Following Weekly SC Flat Dose Marstacimab Administration in Hemophilia Participants Using Regression Modeling and Repeated-Time-To-Event (RTTE) Analyses
Patanjali Ravva
Favorite
Reali, Federico
Fondazione COSBI
(
S-051
)
First-In-Human TBD11 dose range prediction through a multispecies minimal PBPK model
Federico Reali
Favorite
Reddyhoff, Dennis
Certara
(
T-051
)
Efficient Generation of Plausible Virtual Populations Using Machine Learning Surrogate Classification Models
Dennis Reddyhoff
Favorite
Reddy, Micaela
Pfizer
(
T-055
)
Prospective Physiologically Based Pharmacokinetic Modeling Predictions of First-in-Patient Study PK: Examples and Application
Micaela Reddy
Favorite
Reilly, Brian
Clinical and Quantitative Pharmacology, Vertex Pharmaceuticals Inc.
(
S-073
)
Automated simulation with parameter uncertainty from R with NONMEM and NMsim_NWPRI
Brian Reilly
Favorite
Rengaswamy, Maithreye
Vantage Research
(
S-017
)
Optimal therapeutic combinations for Phase 3 UC trial design- recommendations from a QSP platform model
Maithreye Rengaswamy
Favorite
Reynaldo Fernandez, Gledys
University of Florida
(
T-113
)
Model-informed Evidence Generation to Optimize Warfarin Dosing for Hepatic Impairment
Gledys Reynaldo Fernandez
Favorite
Rieger, Theodore
Pfizer Inc
(
T-001
)
Optimization of Ponsegromab PK/PD Assessments in Phase 3 Studies by Clinical Trial Simulation
Theodore Rieger
Favorite
Rivera Rosario, Nicole
Arcus Biosciences
(
S-058
)
Concentration-QTcF Analysis Indicates Casdatifan Does Not Prolong QTcF
Nicole Rivera Rosario
Favorite
Roberts, Jessica
Allucent, LLC
(
S-091
)
Use of the Animal Rule to Develop JST-010 for Pre-Exposure Prophylaxis Against Infection by Yersinia pestis
Jessica Roberts
Favorite
Rodriguez Vera, Leyanis
Clinical Trial & Consulting (CTI)
(
M-114
)
A Dose That Fits All: Model-Based Insights into the Impact of Obesity on Midazolam Oromucosal Pharmacokinetics in Adults
Leyanis Rodriguez Vera
Favorite
Roeshammar, Daniel
InsilicoTrials
(
M-042
)
Leveraging Real-World Data for Osteoarthritis Severity Score Modeling: An InSilicoTrials Platform Application
Daniel Roeshammar
Favorite
(
M-044
)
A Case Study Showcasing the Impact of the InSilicoTrials Platform on Obesity Clinical Trials
Daniel Roeshammar
Favorite
Rojas, Luisa
Parexel International
(
M-113
)
Characterization of PK Characteristics of IMMUNORHO after Intramuscular Administration for the Prevention of RhD Isoimmunisation in Rh(D) Negative Women Pregnant with Rh(D) Positive Fetuses: Population Pharmacokinetic Approach
Luisa Rojas
Favorite
Ruiz-Martinez, Alvaro
Rosa & Co. LLC
(
T-011
)
Accurate modeling of ACTH and cortisol dynamics for Cushing’s disease treatment
Alvaro Ruiz-Martinez
Favorite
(
T-012
)
Evaluation of Parallel Tempering for Efficient Generation of Virtual Populations
Alvaro Ruiz-Martinez
Favorite
(
T-013
)
Adaptable PBPK-QSP gene therapy model applied to i.v. administration of AAV-2 across different species
Alvaro Ruiz-Martinez
Favorite
Rupani, Dheeraj
AstraZeneca PLC
(
M-005
)
Transforming Pharmacometric Processes to deliver medicines to patients: Balancing Speed, Quality, and Innovation
Dheeraj Rupani
Favorite
(
M-006
)
Risk Based Validation Strategy for Pharmacometric Analysis Ready Dataset to improve efficiency and effectiveness
Dheeraj Rupani
Favorite
